Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Regeneron hopes for approval in the indication in the second half of this year. Regeneron also is studying Libtayo as a combo therapy with the company’s fianlimab, going up against Keytruda ...

Libtayo – the sixth PD-L/PD-L1 inhibitor ... 50% or more PD-L1 expression along with a couple of other skin cancer indications. The new trial could give it a much better chance of competing ...

The potential use of Libtayo described above is investigational, and its safety and efficacy has not been evaluated by any regulatory authority for this indication. C-POST is an ongoing randomized, ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

The trial will continue for additional follow-up, Regeneron said, adding that it is planning to file a submission with US Food and Drug Administration for Libtayo in this indication in the first half ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...